Meeting
2018 ASCO Annual Meeting
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).
Authors
Jamie E. Chaft
Memorial Sloan Kettering Cancer Center, New York, NY
Jamie E. Chaft , Suzanne Eleanor Dahlberg , Onkar V Khullar , Martin J. Edelman , Charles B. Simone II, John Heymach , Charles M. Rudin , Suresh S. Ramalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02595944
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8581)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8581
Abstract #
TPS8581
Poster Bd #
186b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
First Author: Jacob Sands
Poster
2017 ASCO Annual Meeting
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
First Author: Jamie E. Chaft
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
First Author: Eric Nadler
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Single-center experience with nivolumab in pretreated patients with non-small cell lung cancer (NSCLC).
First Author: Bernardo Leon Rapoport